The Interdisciplinary Oncology Unit is the clinical trials shared resource of the Cancer Center. It helps formulate studies in an advisory capacity; it is responsible for the conduct of institutional clinical trials; and it implements and maintains a new data management system developed by Dr. Gams. In this submission the IOU is combined with the Ambulatory Oncology Unit, which in the last grant application, was a separate resource. With the opening of the new hospital, the number of beds dedicated to institutional clinical trials is said to have gone from 16 to 34, then increased to 64. A large number of institutional Phase I and II protocols are open and active although the accrual rates do not seem to be robust. Many of the studies have been supported by NCI contracts to do Phase I and II studies. Research nurses are responsible for the identification of eligible patients for clinical studies and for enrollment in clinical trials, and the data managers for are responsible for the recording, quality control and auditing of data.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-24
Application #
6268862
Study Section
Project Start
1998-07-01
Project End
1999-11-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
24
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Lehmann, Vicky; Nahata, Leena; Ferrante, Amanda C et al. (2018) Fertility-Related Perceptions and Impact on Romantic Relationships Among Adult Survivors of Childhood Cancer. J Adolesc Young Adult Oncol 7:409-414
Dix, David B; Seibel, Nita L; Chi, Yueh-Yun et al. (2018) Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. J Clin Oncol 36:1564-1570
Kohnken, Rebecca; Wen, Jing; Mundy-Bosse, Bethany et al. (2018) Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma. Blood 131:771-781
Londhe, Priya; Yu, Peter Y; Ijiri, Yuichi et al. (2018) Classical NF-?B Metabolically Reprograms Sarcoma Cells Through Regulation of Hexokinase 2. Front Oncol 8:104
Valenciaga, Anisley; Saji, Motoyasu; Yu, Lianbo et al. (2018) Transcriptional targeting of oncogene addiction in medullary thyroid cancer. JCI Insight 3:
Kiss, Daniel L; Baez, William D; Huebner, Kay et al. (2018) Loss of fragile histidine triad (Fhit) protein expression alters the translation of cancer-associated mRNAs. BMC Res Notes 11:178
Vasu, Sumithira; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv 2:1645-1650
Denton, Nicholas L; Chen, Chun-Yu; Hutzen, Brian et al. (2018) Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment. Mol Ther Oncolytics 11:62-74
Krasnick, Bradley A; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: A multi-institution analysis from the U.S. extrahepatic biliary malignancy consortium. J Surg Oncol 117:363-371
Badawi, Mohamed; Kim, Jihye; Dauki, Anees et al. (2018) CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128. Oncotarget 9:26032-26045

Showing the most recent 10 out of 2602 publications